Gastrointestinal stromal tumor secondary prevention
|
Gastrointestinal stromal tumor Microchapters |
|
Differentiating Gastrointestinal stromal tumor from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Gastrointestinal stromal tumor secondary prevention On the Web |
|
American Roentgen Ray Society Images of Gastrointestinal stromal tumor secondary prevention |
|
Gastrointestinal stromal tumor secondary prevention in the news |
|
Blogs on Gastrointestinal stromal tumor secondary prevention |
|
Directions to Hospitals Treating Gastrointestinal stromal tumor |
|
Risk calculators and risk factors for Gastrointestinal stromal tumor secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]
Overview
Effective measures for the secondary prevention of gastrointestinal stromal tumors include regular follow ups including physical examination with laboratory and imaging evaluations. GIST on medical therapy tend to have a recurrent course and must be evaluated on a periodic basis with an CT scan or PET scan for early identification of recurrent disease.
Secondary Prevention
Effective measures for the secondary prevention of gastrointestinal stromal tumors (GIST) include:[1]
- Regular follow ups including physical examination with laboratory and imaging evaluations.
- GISTs are known to present with locally recurrent and distant metastasis and thus periodic evaluation through a CT scan should be done for early detection of recurrent disease and prevention of future complications (such as tumor hemorrhage). However, there is no consensus on the time interval between assessment.
- Patients with indeterminate or inaccessible lesions can be evaluated with PET scans to identify malignant lesions from benign lesions.
- A positron emission tomography (PET) scanning can also be used to determine response to therapy and can identify active tumor from necrotic and inactive scar tissue. This is particularly helpful in patients receiving tyrosine kinase inhibitor therapy for incompletely resected, recurrent, or metastatic disease.